Dihematoporphyrin ether

DB15351InvestigationalSmall molecule

Dihematoporphyrin ether is under investigation in clinical trial NCT00118222 (High Light and Low Light Dose PDT in Glioma).

Formula / weight: C₆₈H₇₄N₈O₁₁ · 1179.385 g/mol (avg)
Also known as: bis-1-(8-(1-hydroxyethyl)deuteroporphyrin-3-yl)ethyl ether · DHP ether

Resolves to

Compound

UNII625J2HS54GCAS97067-70-4

Clinical / RWD

RxNorm23066

Structure

InChIKeyVAYJWFGRGMQINH-STKOUIOXSA-NSMILES

CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)OC(C)C1=C2NC(\C=C4/N=C(/C=C5\N\C(=C/C6=N/C(=C\2)/C(C)=C6C(C)O)C(C)=C5CCC(O)=O)C(CCC(O)=O)=C4C)=C1C)/C(CCC(O)=O)=C3C

What you can answer from here — as of August 31, 2026

43Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Dihematoporphyrin ether, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account